Results 271 to 280 of about 79,270 (300)

Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class

Urologic Clinics of North America, 2007
With three effective and safe phosphodiesterase type 5 (PDE5) inhibitors, the clinician now has multiple choices in the treatment of patients who have erectile dysfunction of all severities and etiologies. Based on pharmacokinetics, pharmacodynamics, efficacy, and safety, each of these agents can be used.
openaire   +2 more sources

[Novel indications for phosphodiesterase type 5 inhibitors].

Medizinische Klinik (Munich, Germany : 1983), 2007
Phosphodiesterase type 5 (PDE5) induces the breakdown of cyclic guanosine monophosphate (cGMP) in smooth muscle cells. Hence, PDE5 inhibitors promote vasodilative effects by enhancing intracellular cGMP levels. Three PDE5 inhibitors, sildenafil, vardenafil, and tadalafil, have been approved for the treatment of "erectile dysfunction" (ED).
Stephan, Rosenkranz, Evren, Caglayan, Erland, Erdmann   +2 more
openaire   +1 more source

Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis

EAU Update Series, 2004
Abstract All three PDE5 inhibitors are targeting the same site of action e.g. PDE5 and this is why a quite similar efficacy and safety profile could be expected and was finally proven in many controlled studies. The efficacy as assessed by the endpoint successful intercourse with maintenance of erection (SEP3) ranges between 65 and 75% in broad ...
openaire   +1 more source

Phosphodiesterase Type 5 Inhibitors

2023
openaire   +1 more source

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

An overview of real‐world data sources for oncology and considerations for research

Ca-A Cancer Journal for Clinicians, 2022
Lynne Penberthy, Donna R Rivera, Jennifer L Lund, Msph   +2 more
exaly  

Health insurance status and cancer stage at diagnosis and survival in the United States

Ca-A Cancer Journal for Clinicians, 2022
Jingxuan Zhao, Xuesong Han, Leticia M Nogueira   +2 more
exaly  

An overview of precision oncology basket and umbrella trials for clinicians

Ca-A Cancer Journal for Clinicians, 2020
Kristian Thorlund, Edward J Mills
exaly  

Cancer statistics, 2017

Ca-A Cancer Journal for Clinicians, 2017
Rebecca L Siegel, Kimberly D Miller
exaly  

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly